Safety and Efficacy of LONQUEX (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy

Trial Profile

Safety and Efficacy of LONQUEX (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Merckle
  • Most Recent Events

    • 19 Jan 2017 This trial has been completed in Greece.
    • 11 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top